Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids.
OBJECTIVE
To investigate whether oral or vaginal administration of contraceptive hormones might affect antimüllerian hormone (AMH) levels.


METHODS
Prospective trial with women recruited by advertisement. Women who wished contraception were randomized between oral or vaginal estroprogestative contraception, and those who did not choose contraception were included in the control group.


METHODS
Fertility clinic of a tertiary university hospital.


METHODS
Twenty-four young, healthy volunteer women with regular cycles who had received no hormonal contraception for at least 3 months before the study.


METHODS
Oral or vaginal estroprogestative contraception from day 5 to 25 of a menstrual cycle versus no contraception.


METHODS
Intercycle and intracycle variations of serum AMH levels in normally ovulating volunteers and following the initiation of oral or vaginal estroprogestative contraception.


RESULTS
Fluctuations of AMH levels observed during the menstrual cycle remained within cycle-to-cycle variability in cycling controls and in women receiving oral or vaginal contraception.


CONCLUSIONS
Our findings confirm that AMH levels remain steady during the menstrual cycle and indicate that they are unaffected by exogenous sex steroids used for contraception whether administered orally or vaginally.
Streuli
Isabelle
I
Joint Division of Reproductive Endocrinology and Infertility, University Hospitals of Geneva and Lausanne, Geneva, Switzerland. isabelle.streuli@hcuge.ch
Fraisse
Timothée
T
Pillet
Christine
C
Ibecheole
Victoria
V
Bischof
Paul
P
de Ziegler
Dominique
D
D000282:Administration, Intravaginal; D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage*; D017135:Desogestrel / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000097:blood*; D010197:Pancuronium / Q000008:administration & dosage / Q000031:analogs & derivatives
D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D004338:Drug Combinations; C516519:NuvaRing; D004997:Ethinyl Estradiol; D054304:Anti-Mullerian Hormone; D017135:Desogestrel; D010197:Pancuronium; C003549:dacuronium